Deals channel feed

With fresh in­vestor cash in hand, Volas­tra part­ners with Mi­crosoft to de­vel­op metasta­t­ic can­cer bio­mark­er plat­form

5 years ago
Financing
AI

With one pan­dem­ic still rag­ing, J&J bets $780M on a po­ten­tial flu ther­a­py for the next

5 years ago

Neil Ku­mar’s Bridge­Bio team locks in a $2.4B part­ner­ship as their next drug gets a snap re­view at the FDA

5 years ago

Look­ing to crack down on big bio­phar­ma M&A deals, FTC sues to block Il­lu­mi­na's $8B Grail ac­qui­si­tion

5 years ago
FDA+

Am­gen takes a swing at re­gen­er­a­tive im­munol­o­gy with $721M ac­qui­si­tion of Rodeo Ther­a­peu­tics

5 years ago

Mer­ck lines up a buy­out deal for soon-to-be wom­en's health spin­out

5 years ago

No­var­tis dives even deep­er in­to ra­di­oli­gands, notch­ing li­cens­ing deal with iTher­a­nos­tics for mul­ti­ple com­pounds

5 years ago

Af­ter pi­lot project, Take­da inks $500M pact to tap in­to a Ke­van Shokat pro­tégé's co­va­lent small mol­e­cule fish­ing plat­form

5 years ago

Glax­o­SmithK­line of­fers fill-fin­ish ca­pac­i­ty to No­vavax for UK sup­ply of Covid-19 vac­cine

5 years ago
Coronavirus
Manufacturing

It's a brave new world for So­ma­Log­ic, as the pro­teomics biotech rides Eli Cas­d­in's newest SPAC to Nas­daq with $1.2B val­u­a­tion

5 years ago
Financing

With $190M in in­vestor cash to play with, Chi­na's Chime Bi­o­log­ics looks to build 15x man­u­fac­tur­ing ca­pac­i­ty by 2024

5 years ago
Manufacturing

Hop­ing to take drug R&D in­to the cloud, In­sight­ful Sci­ence snaps up da­ta man­age­ment out­fit Dot­mat­ics

5 years ago
R&D

Take­da takes a swing at RNA small mol­e­cules with dis­cov­ery pact for mul­ti­ple po­ten­tial Evotec pro­grams

5 years ago
R&D

Out­bid­ding 14 oth­ers and then them­selves: How Am­gen spent $2 bil­lion on a biotech that had been on the brink

5 years ago

Liv­ing in its post-Shire world, Take­da con­tin­ues ag­gres­sive li­cens­ing push in $2.3B deal with An­i­ma

5 years ago

Top biotech in­vestor Pe­ter Kolchin­sky tees up a new SPAC — 3 days af­ter a $300M raise for ra­dio­phar­ma­ceu­ti­cals play

5 years ago
Financing

Dean Li in­vites an­oth­er un­der-the-radar biotech to Mer­ck­'s deal­mak­ing ta­ble as Am­ath­us signs neu­rode­gen­er­a­tion pact

5 years ago

Mon­tre­al AI start­up with a tout­ed ad­vi­sor li­cens­es its 'few-shot' plat­form to Re­pare for syn­thet­ic lethal­i­ty mol­e­cules

5 years ago
Discovery

With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to Glob­al Blood Ther­a­peu­tics

5 years ago

Ab­b­Vie looks to shed Al­ler­gan's lega­cy wom­en's health unit as it hun­kers down for Hu­mi­ra biosim dooms­day — re­port

5 years ago

Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

5 years ago
People

Gilead, Mer­ck put aside ri­val­ry to chal­lenge Glax­o­SmithK­line for long-act­ing HIV meds

5 years ago

Roche drops $1.85B for Gen­Mark's test­ing tech as pan­dem­ic, an­tibi­ot­ic re­sis­tance threats loom

5 years ago

Take­da goes all in with build-to-buy play, pick­ing up Mav­er­ick and its clin­ic-ready T cell en­gagers for $525M

5 years ago
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times